Could a vaccine prevent snakebite-associated muscle damage?
Original story from the University of Reading (UK).
The same technology used in COVID-19 vaccines could help prevent muscle damage from snakebites.
Scientists from the University of Reading (UK) and the Technical University of Denmark (Kongens Lyngby; Denmark) tested whether mRNA technology could be used to protect against the damage caused by the venom of the Bothrops asper snake, which is found in Central and South America. This snake’s venom destroys muscle tissue, often leaving victims with permanent disabilities even after receiving standard treatment.
The research team developed mRNA-lipid nanoparticles (LNPs) to express and deliver single-chain variable fragments (scFvs) of antibodies against a venom myotoxin and tested their efficacy in preventing myotoxin and venom-induced muscle damage in vitro and in vivo. The treatment could significantly limit the injury and impact of snakebites, which kill around 140,000 people worldwide and cause 400,000 permanent disabilities each year.
Sakthi Vaiyapuri, lead author of the study from the University of Reading, commented: “For the first time, we’ve shown that mRNA technology can protect muscle tissue from snake venom-induced damage. This opens a completely new door for treating snakebites, particularly the local injuries that current antivenoms struggle to prevent.”
Andreas Laustsen, who co-led this study from the Technical University of Denmark shared: “We tested this treatment on snake venom, but this technology could be even more useful for other conditions where toxins cause harm gradually. For example, it might help block harmful toxins produced by bacteria during infections.”
Antivenom intelligence? The role of AI in developing snakebite treatments
We spoke to Tim Jenkins, an Assistant Professor at the Technical University of Denmark, about his research incorporating artificial intelligence into antibody discovery programs to develop new snakebite antivenoms.
Shielding muscles from damage
Current antivenoms work well against toxins in the bloodstream but struggle to reach damaged muscle tissue around the bite site. In laboratory tests using cultured human muscle cells, the new treatment reduced damage from both a single toxin and whole venom. The protective antibodies appeared within 12–24 hours of mRNA injection. In mice, a single injection of mRNA protected muscle tissue from toxin-induced injury when given 48 hours before exposure to the venom.
The treatment reduced key signs of muscle damage; mice that received the mRNA treatment before being exposed to the toxin showed lower levels of enzymes such as creatine kinase and lactate dehydrogenase, which are released when muscle is injured. The treatment also preserved healthy muscle structure.
The researchers say their approach could work alongside traditional antivenoms. Standard treatments handle toxins in the blood, while mRNA-delivered antibodies could protect local tissues that antivenoms cannot reach.
Tackling remaining challenges
The research team says various challenges remain before the new treatment could help patients. The antibodies take hours to develop, and the treatment currently targets only one toxin. Future versions would need to protect against multiple venom components. Furthermore, storage in remote areas without refrigeration also presents difficulties.
Professor Vaiyapuri concluded: “We now need to expand this approach to target multiple venom toxins and solve storage challenges for rural areas, as well as ensure faster production of antibodies in tissues. The potential to reduce disabilities among snakebite victims is significant.”
The team plans to develop treatments targeting additional toxins and test whether the approach works when given after a bite occurs.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
